Paragon 28 Sells to Zimmer Biomet

The ongoing consolidation in the foot and ankle market is progressing steadily. In a January 28 company report, Zimmer Biomet (ZB) announced it has reached a definitive agreement to acquire all outstanding shares of common stock of Paragon 28 (P28), with the transaction reflecting an equity value of approximately $1.1 billion.

History of Paragon 28

Founded in 2010, Paragon 28 has concentrated on the foot and ankle market, consistently innovating and establishing a solid platform. In 2024, the company achieved sales of approximately $255 million, with year-over-year growth above the market average. 

What’s next for ZB/P28

Integrating sales forces and company cultures is not for the weak of heart. The good news here is that P28 can instantly elevate ZB to a competitive position in foot and ankle.